BioCentury
ARTICLE | Clinical News

Amphinex: Phase II started

April 9, 2012 7:00 AM UTC

PCI Biotech began an open-label, European Phase II trial to evaluate a single treatment of 0.25 mg/kg IV Amphinex in combination with bleomycin followed by laser therapy in about 80 head and neck canc...